Agatolimod is a phylogenetically conserved transmembrane protein which acts as a toll-like receptor 9 agonist. As such it facilitates the recognition of pathogens by the immune system.[1] It has been investigated as a treatment for renal cell carcinoma in a small trial of 39 adults but showed only modest antitumor activity.[2]
Sequence[edit]
Agatolimod is composed of 24 nucleic acids in the following sequence:
(T-C-G-T-C-G-T-T-T-T-G-T-C-G-T-T-T-T-G-T-C-G-T-T)
References[edit]
Jump up ^ Bauer, S.; Kirschning, C. J.; Hacker, H.; Redecke, V.; Hausmann, S.; Akira, S.; Wagner, H.; Lipford, G. B. (24 July 2001). "Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition". Proceedings of the National Academy of Sciences 98 (16): 9237–9242. doi:10.1073/pnas.161293498.
Jump up ^ Thompson, John A.; Kuzel, Timothy; Drucker, Beverly J.; Urba, Walter J.; Bukowski, Ronald M. (October 2009). "Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study". Clinical Genitourinary Cancer 7 (3): E58–E65. doi:10.3816/CGC.2009.n.025.
Sequence[edit]
Agatolimod is composed of 24 nucleic acids in the following sequence:
(T-C-G-T-C-G-T-T-T-T-G-T-C-G-T-T-T-T-G-T-C-G-T-T)
References[edit]
Jump up ^ Bauer, S.; Kirschning, C. J.; Hacker, H.; Redecke, V.; Hausmann, S.; Akira, S.; Wagner, H.; Lipford, G. B. (24 July 2001). "Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition". Proceedings of the National Academy of Sciences 98 (16): 9237–9242. doi:10.1073/pnas.161293498.
Jump up ^ Thompson, John A.; Kuzel, Timothy; Drucker, Beverly J.; Urba, Walter J.; Bukowski, Ronald M. (October 2009). "Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study". Clinical Genitourinary Cancer 7 (3): E58–E65. doi:10.3816/CGC.2009.n.025.
No comments:
Post a Comment